Annual Meeting of the Hematology Branch of CPAM 2026 | Professor Fangping Chen: Advancing Standardized Care in Hematologic Malignancies—Challenges, Translation, and Resource Integration
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.
Annual Meeting of the Hematology Branch of CPAM 2026 | Professor Wanling Sun: Interpreting the Updated Adult ITP Guidelines—Focusing on Key Revisions and Optimizing Clinical Practice
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.
Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML
Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from myeloid stem cells, characterized by significant biological diversity and generally poor prognosis. The global disease burden of AML continues to rise, with the age-standardized incidence increasing by 87.3% between 1990 and 2021, underscoring the urgent need for improved therapeutic strategies.
Annual Meeting of the Hematology Branch of CPAM 2026 | Professor Shuqian Xu: Advances in First-Line Treatment of Severe Aplastic Anemia—Enhancing Efficacy and Optimizing Clinical Practice
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.
Annual Meeting of the Hematology Branch of CPAM 2026 | Professor Sanbin Wang: Interpreting the DSA Consensus and Clinical Strategies
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.
Annual Meeting of the Hematology Branch of CPAM 2026 | Professor Yu Hou: Focus on Refractory ITP—Key Diagnostic Considerations and Differential Strategies
From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Workshop, was held in Changsha.
Professor Rong Fu: From Data to Mechanism—A Comprehensive Interpretation of Thrombosis in PNH and Emerging Strategies for Prevention and Management
From March 27 to 28, 2026, the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Summit Forum on Hematologic Malignancies and Immunology was held in Beijing, bringing together leading experts from China and abroad to discuss advances in thrombosis, hemostasis, hematologic malignancies, and immunology.
North–South Summit 2026 | Professor Leiping Wang: HER2-Positive Metastatic Breast Cancer—Has the First-Line ADC Era Truly Arrived?
With the release of data from studies such as DESTINY-Breast09 (DB-09), antibody–drug conjugates (ADCs) are gaining increasing prominence in the first-line treatment of HER2-positive metastatic breast cancer (MBC). However, while the traditional THP regimen (trastuzumab + pertuzumab + taxane) remains firmly established as the guideline-preferred standard, the question remains: has the “era of ADC dominance” truly begun? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Leiping Wang from Fudan University Shanghai Cancer Center addressed this question. She emphasized that although ADCs have opened the door to first-line therapy with impressive progression-free survival (PFS) benefits, their full integration into clinical practice still requires further validation, particularly in the context of refined disease management and treatment sequencing.
North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?
In the era of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC), an important clinical question has emerged: is platinum still indispensable? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Jia Wang from Zhongshan Hospital, Dalian University presented an in-depth analysis of this issue. Drawing on treatment goals, mechanistic rationale, clinical evidence, and individualized strategies, she systematically reviewed the role and challenges of platinum agents in neoadjuvant immunotherapy for TNBC and proposed future directions toward precision “de-escalation” therapy.